Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Tomislav Dragovich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1569-2172; OpenAlex author ID A5065671989; NIH RePORTER profile ID 3118541. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
1
Collaborators
49
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper, 1 grant · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  2. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  3. Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Co-author DOI 10.21037/jgo-20-361↗
  4. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  5. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  6. Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications. Last author DOI 10.1155/2015/269641↗
  7. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1200/jco.2014.55.7504↗
  8. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Co-author DOI 10.1007/s00280-014-2499-4↗
  9. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage I… Co-author DOI 10.1016/j.pan.2014.07.003↗
  10. Is there a case for personalized therapy of pancreatic cancer? Co-author PMID 22706549↗
  11. Management strategies in pancreatic cancer. First author DOI 10.2146/ajhp100254↗

Trials 1

  1. PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma Principal investigator NCT00226005↗

Grants 1

  1. Therapeutic Targeting of Hypoxic and Oxidative Stress P01CA017094↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elena Gabriela Chiorean · 2 shared papers, 2015–2026 · strength 0.27
  2. Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
  3. Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.23
  4. Ben George · 1 shared paper, 2026 · strength 0.23
  5. Andrew L. Coveler · 1 shared paper, 2026 · strength 0.23
  6. Sita Kugel · 1 shared paper, 2026 · strength 0.23
  7. Rachael Ann Safyan · 1 shared paper, 2026 · strength 0.23
  8. David Bing Zhen · 1 shared paper, 2026 · strength 0.23
  9. Sunil R. Hingorani · 1 shared paper, 2026 · strength 0.23
  10. Howard S. Höchster · 1 shared paper, 2026 · strength 0.23
  11. John C. S. Chang · 2 shared papers, 2015–2021 · strength 0.22
  12. Akshjot Puri · 1 shared paper, 2021 · strength 0.14
  13. Madappa N. Kundranda · 1 shared paper, 2021 · strength 0.14
  14. Robert T. Dorr · 1 shared grant, 2011 · strength 0.11
  15. Nathan Bahary · 3 shared papers, 2014–2015 · strength 0.11
  16. Amanda F. Baker · 2 shared papers, 2011–2014 · strength 0.08
  17. David P. Ryan · 2 shared papers, 2014–2015 · strength 0.08
  18. Peter J. Rosen · 2 shared papers, 2014–2015 · strength 0.08
  19. Daniel A. Laheru · 2 shared papers, 2014 · strength 0.07
  20. Eileen Mary O'Reilly · 2 shared papers, 2014–2015 · strength 0.07
  21. Maeve Aine Lowery · 2 shared papers, 2014–2015 · strength 0.07
  22. Daniel D. Von Hoff · 2 shared papers, 2014–2015 · strength 0.07
  23. Christopher J. Campen · 1 shared paper, 2011 · strength 0.04
  24. Mitesh J. Borad · 1 shared paper, 2015 · strength 0.04
  25. Darren S. Sigal · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.